TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00912184

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard polyamide high flux membrane
Description: Standard haemofiltration; CVVH; blood flow 200 ml/min, ultrafiltrate 25 ml/kg/hr, anticoagulation as clinically indicated, bicarbonate buffered replacement fluid

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High cut-off (super high flux) polyamide membrane
Description: CVVH with standard haemofiltration settings; blood flow 200 ml/min, ultrafiltrate 25 ml/kg/hour, anticoagulation as clinically indicated, bicarbonate-buffered replacement fluid
Study: NCT03545425

Intervention type: PROCEDURE
Intervention: Biofluid samplings
Description: Blood and Urine

Intervention type: PROCEDURE
Intervention: Biofluid samplings
Description: Blood and Urine

Intervention type: PROCEDURE
Intervention: Biofluid samplings
Description: Blood and Urine

Intervention type: PROCEDURE
Intervention: Biofluid samplings
Description: Blood and Urine
Study: NCT01252732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single-Dose IV Oritavancin Diphosphate
Description: Intravenous oritavancin and IV placebo or IV vancomycin will be administered for a minimum of 7 days up to a maximum of 10 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Vancomycin
Description: Intravenous oritavancin and IV placebo or IV vancomycin will be administered for a minimum of 7 days up to a maximum of 10 days.
Study: NCT01522937

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: individualized Stereotactic Body Radiation Therapy (SBRT)
Description: The individualized SBRT involves two treatment phases. The first phase of treatment involves receiving three fractions of SBRT, followed by a 1-month break and assessment of liver function with a blood test - Indocyanine Green (IC-Green). The second phase of treatment involves receiving two more fractions of SBRT, whose doses are adjusted to account for tolerance of the first phase of treatment.
Study: NCT04667884

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotics or Probiotics
Description: All the supplements were provided in solid drinks，and required to drink with plain water 35-40℃, and lifestyle intervention was provided to all the groups by reading materials.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotics or Probiotics
Description: All the supplements were provided in solid drinks，and required to drink with plain water 35-40℃, and lifestyle intervention was provided to all the groups by reading materials.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotics or Probiotics
Description: All the supplements were provided in solid drinks，and required to drink with plain water 35-40℃, and lifestyle intervention was provided to all the groups by reading materials.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotics or Probiotics
Description: All the supplements were provided in solid drinks，and required to drink with plain water 35-40℃, and lifestyle intervention was provided to all the groups by reading materials.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Prebiotics or Probiotics
Description: All the supplements were provided in solid drinks，and required to drink with plain water 35-40℃, and lifestyle intervention was provided to all the groups by reading materials.
Study: NCT00147836

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Insulin (Novolin-R, Novo Nordisk)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: H-Tron Plus V100; Disetronic Medical System, Burgdorf, Switzerland

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pre-meal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Novolin-R

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Insulin NPH (Novolin-N, Novo Nordisk)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gliclazide (Diamicron, Servier)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diamicron and Glucophage
Study: NCT00093249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clevidipine
Description: Clevidipine (0.5 mg/mL in 20% lipid emulsion)will be administered intravenously at an initial infusion rate of 0.4 µg/kg/min and will be titrated, as tolerated, at the discretion of the investigator, in doubling increments approximately every 90 seconds up to a maximum of 3.2 µg/kg/min, in order to achieve the desired blood pressure lowering effect. Clevidipine may be titrated upwards or downwards and may be temporarily interrupted and restarted to attain the desired blood pressure effect. The maximum study drug infusion rate of 8.0 µg/kg/min may not be exceeded.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo (20% lipid emulsion - vehicle) will be administered intravenously in a fashion identical to clevidipine as described above.
Study: NCT00554710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: infliximab+azathioprine
Description: infliximab 5 mg/kg at week 0,2 and 6 + azathioprine 2-2.5 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone or budesonide
Description: methylprednisolone 32 mg followed by taper or budesonide 9 mg/day followed by taper
Study: NCT01112306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-293987
Description: Tablets, twice daily
Study: NCT00419445

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GTS21/Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GTS21/Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GTS21/Placebo
Study: NCT02740803

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium fluoride toothpaste 1,450 ppmF

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium fluoride toothpaste 1,450 ppmF

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sodium monofluorophosphate toothpaste 1,450 ppmF

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sodium monofluorophosphate toothpaste 1,450 ppmF

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stannous fluoride combined with sodium fluoride toothpaste 1,450 ppmF

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stannous fluoride combined with sodium fluoride toothpaste 1,450 ppmF

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sodium fluoride combined sodium monofluorophosphate toothpaste 1,450 ppmF

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sodium fluoride combined sodium monofluorophosphate toothpaste 1,450 ppmF

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amine fluoride toothpaste 1,400 ppmF

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amine fluoride toothpaste 1,400 ppmF

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-fluoridated toothpaste 0 ppmF

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-fluoridated toothpaste 0 ppmF
Study: NCT04166240

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SAFER TRACKS Intervention
Description: SAFER Change Package delivered using a Virtual Breakthrough Series \[VBTS\] Collaborative supplemented with automated surveillance data on test results.
Study: NCT04371588

Intervention type: OTHER
Intervention: No Response to Train of Four Stimulation
Description: No response is observed during Train of Four stimulation monitoring during surgery

Intervention type: OTHER
Intervention: 1-2 Response to Train of Four Stimulation
Description: 1 to 2 response is observed during Train of Four stimulation monitoring during surgery
Study: NCT03078829

Intervention type: DRUG
Intervention: Treatment with a GnRh agonists
Description: All patients will be treated with GnRH agonists
Study: NCT04231370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab, 200mg, iv day1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25mg/d oral d1-14
Study: NCT01751945

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EmONC package
Description: The EmONC package consists of:~1. Maternal and neonatal health pack(clean delivery kit, emollient, chlorhexidine, sms messages) for safe motherhood and newborn wellbeing.~2. Enhanced trainings of community-level health care providers to provide effective maternal and neonatal health services and referral of complicated cases to health facilities and creation of linkages amongst health care providers.~3. Community mobilisation
Study: NCT03945292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fazisiran Injection
Description: solution for subcutaneous (sc) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fazisiran Injection
Description: solution for subcutaneous (sc) injection
Study: NCT00852488

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placement of transthoracic catheter
Description: Placement of transthoracic catheter into the inferior vena cava
Study: NCT01316068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous use of sulodexide followed by oral use
Description: Patients will be given sulodexide 1200 LSU per day intravenously for 2 weeks,then receive 1000 LSU per day orally for 50 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: use of sulodexide orally only
Description: Patients receive 1000 LSU per day orally for 52 weeks
Study: NCT04453553

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Q16 testing
Description: Nasal swab tested on a rapid near patient device

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Nasopharyngeal swab and main laboratory
Description: Standard of care testing
Study: NCT01138917

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReCell and Split-thickness skin graft
Description: The surgeon will be required to select two similar non-contiguous injury areas with both areas being at least 100cm2 and second degree depth/severity. One area will be treated using ReCell and the second using Split-thickness Skin Graft.
Study: NCT00286598

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feet First
Description: Phase 1: (enrollment to 3 months) 8 sessions with a physical therapist learning leg strengthening and balance exercises, and initiating a walking program Phase 2: Motivational enhancement calls from a nurse every 2 weeks.
Study: NCT00200343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid 150mg / day
Description: Ursodeoxycholic acid, 150mg/ day, three times a day at meals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid 600mg / day
Description: Ursodeoxycholic acid, 600mg/ day, three times a day at meals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid 900mg / day
Description: Ursodeoxycholic acid, 900mg/ day, three times a day at meals
Study: NCT01615276

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enraf Nonius Tensmed S84 for Neuromuscular electrical stimulation (NMES)
Description: One our of one-legged neuromuscular electrical stimulation (NMES)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: No Enraf Nonius Tensmed S84 for Neuromuscular electrical stimulation (NMES) NMES
Description: No neuromuscular electrical stimulation (NMES) will be applied in the control leg
Study: NCT01724554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Aflibercept Injection
Description: Aflibercept administered to the eye intravitreally either every month or every other month.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Aflibercept Injection
Description: Aflibercept administered to the eye intravitreally either every month or every other month.
Study: NCT02449343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib p.o. qd

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo p.o. qd
Study: NCT02639416

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polymeric formula
Description: Polymeric formulae are recommended in the management of inflammatory bowel disease in children

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Elemental formula
Description: Elemental formulae are recommended in cow's milk and other food intolerances in children.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard management
Description: Standard management with F-100 and/or RUTF
Study: NCT01055067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivantinib (ARQ 197)
Description: Capsule, 120 mg, BID (360 mg), approximately 112 days
Study: NCT01453062

Intervention type: DRUG
Intervention: Arzerra
Description: Treatment with Arzerra
Study: NCT01159431

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trigeminal Nerve Stimulation
Description: External stimulation of the supraorbital branch of the Trigeminal Nerve using a digital TENs unit

Intervention type: DEVICE
Group type: OTHER
Intervention: Trigeminal Nerve Stimulation
Description: External stimulation of the supraorbital branch of the Trigeminal Nerve using a digital TENs unit
Study: NCT01986699

Intervention type: PROCEDURE
Intervention: Laparoscopic Assisted Polypectomy

Intervention type: PROCEDURE
Intervention: Laparoscopic Assisted Polypectomy
Study: NCT01550848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane and Gemcitabine
Description: ABX (Abraxane) 125 mg/m2，intravenous infusion，30min，day 1, 8, 15~GEM (Gemcitabine) 800 mg/m2，intravenous infusion，30min，day 1, 8, 15
Study: NCT00531427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: transdermal system 10 and 20 applied for 7-day wear

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: transdermal system (placebo) applied for 7-day wear
Study: NCT04465838

Intervention type: OTHER
Intervention: NIS
Description: This is a non-interventional study (NIS).
Study: NCT03720652

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 8-Week Mindful Self-Compassion (MSC)
Description: The 8-week MSC is a course of eight 2.5 hour weekly sessions that is based off self-compassion, a construct closely related to mindfulness. Self-compassion (SC) has three main interrelated components: self-kindness, common humanity, and mindfulness. MSC is an 8-session program that integrates SC and mindfulness.~It includes the following components:~* Discovering Mindful Self-Compassion~* Practicing Mindfulness~* Practicing Lovingkindness~* Discovering your Compassionate Voice~* Living Deeply~* Meeting Difficult Emotions~* Exploring Challenging Relationships~* Embracing Your Life

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 6-Week Mindful Self-Compassion (MSC)
Description: The 6-week MSC is a course of six 1 hour weekly sessions that is based off self-compassion, a construct closely related to mindfulness. Self-compassion (SC) has three main interrelated components: self-kindness, common humanity, and mindfulness. MSC is an 6-session program that integrates SC and mindfulness.~It includes the following components:~* What is Self-Compassion~* Practicing Self-Compassion~* Discovering your Compassionate Voice~* Self-Compassion and Resilience~* Self-Compassion and Burnout~* Going Forward This program is a shortened version of the 8-week program, specifically created for the needs of health care staff.
Study: NCT03073733

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human retinal progenitor cells
Description: live suspension of 3.0 or 6.0 x 10e6 human retinal progenitor cells (hRPC) suspended in clinical grade medium injected intravitreally under local anesthesia

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human retinal progenitor cells
Description: live suspension of 3.0 or 6.0 x 10e6 human retinal progenitor cells (hRPC) suspended in clinical grade medium injected intravitreally under local anesthesia

Intervention type: OTHER
Group type: OTHER
Intervention: Mock injection
Description: pressing the hub of a syringe with no needle against the eye to mimic intravitreal injection
Study: NCT01338298

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Aripiprazole dosing will begin at 5 mg/day once daily and increased to 10mg by mouth once daily at the end of week 2 and then increased to 15 mg/day once daily at the end of week 8 in women who have not yet regained their menstrual period. If a woman gets her menstrual period on the 5 or 10 mg dose she will remain on this dose for the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be sucrose filled capsules that are identical to the active medication. It is double blind so no one will know if the capsule is placebo or aripiprazole.
Study: NCT00539968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel plus lonafarnib
Description: Docetaxel: 60-75 mg/m2~Lonafarnib: 150-375 mg PO BID
Study: NCT00582075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: TMZ 200mg/m2 days 1-5 repeat q28 days. Patients who have received prior chemotherapy will receive 150 mg/m2 days 1-5
Study: NCT04359901

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SARILUMAB
Description: Single dose of 400 mg subcutaneous sarilumab
Study: NCT02872285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: LYC-30937-EC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04367909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Nimotuzumab will be administered intravenously at a fixed dose of 200 milligrams (mg) on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 milligrams per square meter (mg/m\^2) will be administered intravenously on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75 milligrams per square meter (mg/m\^2) will be administered intravenously on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 5 will be administered intravenously on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin AUC 5 will be administered intravenously on Day 1 of each 21-day cycle.
Study: NCT04578821

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: Educational intervention
Study: NCT00708487

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Embryo incubator oxygen concentration
Description: Two concentrations of oxygen are currently used to culture the embryos of infertile patients in commercial human IVF programs - 21% and 5%.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Embryo incubator oxygen concentration
Description: Two concentrations of oxygen are currently used to culture the embryos of infertile patients in commercial human IVF programs - 21% and 5%.
Study: NCT04037332

Intervention type: OTHER
Intervention: Blood sample (combined with malaria RDT) followed by gentoyping analysis
Description: Finger-prick blood samples collected from children with signs of severe febrile illness and a positive mRDT presenting to community-based providers and referral facilities ; analysis for mutations in portions of a P. falciparum gene encoding kelch (K13)-propeller domain

Intervention type: OTHER
Intervention: Blood sample (combined with malaria RDT) followed by gentoyping analysis
Description: Finger-prick blood samples collected from children with signs of severe febrile illness and a positive mRDT presenting to community-based providers and referral facilities ; analysis for mutations in portions of a P. falciparum gene encoding kelch (K13)-propeller domain

Intervention type: OTHER
Intervention: Blood sample (combined with malaria RDT) followed by gentoyping analysis
Description: Finger-prick blood samples collected from children with signs of severe febrile illness and a positive mRDT presenting to community-based providers and referral facilities ; analysis for mutations in portions of a P. falciparum gene encoding kelch (K13)-propeller domain

Intervention type: OTHER
Intervention: Blood sample (combined with malaria RDT) followed by gentoyping analysis
Description: Finger-prick blood samples collected from children with signs of severe febrile illness and a positive mRDT presenting to community-based providers and referral facilities ; analysis for mutations in portions of a P. falciparum gene encoding kelch (K13)-propeller domain
Study: NCT01182844

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei Shirota
Description: 3 bottles of Yakult(R) light per day
Study: NCT00970619

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ekos endowave system thrombolysis
Description: Catheter directed thrombolysis will be performed with an Ekos Endowave ® system (EKOS Corporation, Bothell, WA). The system uses a standard guide wire to position the Intelligent Drug Delivery Catheter across the length of the target clot. The guide wire is introduced through the popliteal vein. Along the guide wire the catheter is positioned. The location of the dispersion catheter is controlled and if necessary adjusted by X-ray. The guide wire is then pulled out and replaced with the Microsonic core (a miniscule high frequency (2MHz) ultrasound transducer). The system automatically monitors and controls the microsonic energy delivery. This system does not fragment the thrombus but only gives a structural change by which a better penetration of the thrombolytic agent is achieved.
Study: NCT03805113

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetotherapy device
Description: Use of magnetotherapy device 15 consecutive working days in elegible patients with erosive hand osteoarthritis.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Use of unplugged magnetotherapy device 15 consecutive working days in elegible patients with erosive hand osteoarthritis.
Study: NCT01071018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK2206 every other day
Description: Dose escalation study: MK2206 will be administered as an oral formulation in rising dose levels of 45 mg and 60 mg, once daily every other day in repeating 4 week cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK2206 once weekly
Description: Dose escalation study: MK2206 will be administered as an oral formulation in rising dose levels of 135 mg and 200 mg, once weekly in repeating 4 week cycles.
Study: NCT00833664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbinafine HCl 250mg tablets
Description: 1 x 250 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamisil® 250 mg Tablets
Description: 1 x 250 mg
Study: NCT04469998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXR-270 Low Dose
Description: AXR-270 Topical Eyelid Cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXR-270 High Dose
Description: AXR-270 Topical Eyelid Cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AXR-270 Vehicle
Description: AXR-270 Topical Eyelid Cream Vehicle